SCHF - ETF AI Analysis
Top Page
Schwab International Equity ETF (SCHF)
SCHF, the Schwab International Equity ETF, has a solid overall rating driven largely by strong, diversified holdings in global leaders like HSBC, Novartis, and AstraZeneca, which benefit from healthy financial performance, positive earnings, and solid long-term prospects. Additional support comes from companies such as ASML, Roche, Shell, Royal Bank of Canada, and Mitsubishi UFJ, though some face valuation concerns, potential overbought conditions, or growth challenges. The main risk factor is exposure to individual stocks with signs of overvaluation or short-term technical weakness, which could lead to periods of volatility even within this broadly diversified international portfolio.
SCHF vs. SPDR S&P 500 ETF (SPY)
- AUM
- 67.84B
- Region
- Developed Markets
- Expense Ratio
- 0.03%
- Beta
- 0.78
- Issuer
- Schwab
- Inception Date
- Nov 03, 2009
- Dividend Yield
- 3.14%
- Asset Class
- Equity
- Index Tracked
- FTSE All-World Developed x US
SCHF Summary
The Schwab International Equity ETF (SCHF) is a fund that lets you invest in hundreds of companies from developed countries outside the U.S., following the FTSE Developed ex US index. It owns well-known names like Samsung Electronics and Nestlé, along with many banks, tech firms, and industrial companies across Europe, Asia, and other regions. Someone might invest in SCHF to diversify beyond the U.S. stock market and seek long-term growth from global businesses. A key risk is that international stocks can be volatile and their prices can go up and down with global markets and currency changes.
How much will it cost me?
The Schwab International Equity ETF (SCHF) has an expense ratio of 0.03%, meaning you’ll pay $0.30 per year for every $1,000 invested. This is much lower than average because SCHF is passively managed, tracking an index rather than relying on active stock picking.
What would affect this ETF?
The Schwab International Equity ETF (SCHF) could benefit from global economic growth, particularly in developed markets outside the U.S., as well as advancements in sectors like technology and healthcare, which are among its top holdings. However, it may face challenges from rising interest rates, currency fluctuations, or geopolitical tensions that could negatively impact international markets and sectors like financials and energy. Regulatory changes in key regions or slower growth in developed economies could also affect its performance.
SCHF Top 10 Holdings
SCHF leans heavily on international blue chips, with a clear tilt toward semiconductors and global banks. Samsung Electronics is steady, while SK hynix and ASML add a more volatile, rising tech edge that can swing returns. On the financial side, HSBC and Mitsubishi UFJ are helping, but Royal Bank of Canada has been more mixed, occasionally losing steam. Health care names like Roche and Novartis provide a defensive anchor, though AstraZeneca has been lagging lately. Overall, it’s a diversified developed-markets ex-U.S. play, not dominated by any single country.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 KR:005930 | Samsung Electronics | 2.68% | $1.82B | KRW 1347.92T | 117.55% | ―― |
 NL:ASML | ASML Holding NV | 2.23% | $1.51B | EUR 570.61B | 63.15% | 76Outperform |
 KR:000660 | SK hynix Inc. | 1.93% | $1.31B | KRW 891.40T | 154.00% | ―― |
 GB:HSBA | HSBC Holdings | 1.11% | $750.17M | GBP 237.35B | 37.89% | 80Outperform |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 GB:SHEL | Shell (UK) | 1.06% | $713.69M | GBP 221.86B | 40.84% | 73Outperform |
 CH:NOVN | Novartis AG | 0.99% | $669.79M | CHF 232.26B | 22.91% | 80Outperform |
 RY | Royal Bank Of Canada | ― | ― | ― | ― | 75Outperform |
 CH:NESN | Nestlé SA | 0.90% | $608.02M | CHF 213.78B | 3.09% | 71Outperform |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
SCHF Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For SCHF, the sentiment is Negative. The current price of 26.88 is below the 20-day moving average (MA) of 27.28, below the 50-day MA of 27.82, and above the 200-day MA of 26.73, indicating a neutral trend. The MACD of -0.23 indicates Positive momentum. The RSI at 39.45 is Neutral, neither overbought nor oversold. The STOCH value of 58.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCHF.
SCHF Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| SCHF | $26.88 | $29.00(7.89% Upside) | $67.84B | 0.03% | 60Neutral |
 VEA | $69.26 | $88.56(27.87% Upside) | $230.36B | 0.03% | 58Neutral |
 SPDW | $49.21 | $60.79(23.54% Upside) | $40.88B | 0.03% | 60Neutral |
 IDEV | $89.16 | $108.32(21.49% Upside) | $34.00B | 0.04% | 66Neutral |
 AVDE | $89.24 | $110.98(24.36% Upside) | $19.59B | 0.23% | 65Neutral |
 DFAI | $41.41 | $50.18(21.17% Upside) | $18.08B | 0.18% | 64Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SCHF | Schwab International Equity ETF | 26.88 | 3.83 | 16.64% | |
| VEA | Vanguard FTSE Developed Markets ETF | 69.26 | 9.62 | 16.14% | |
| SPDW | SPDR Portfolio Developed World ex-US ETF | 49.21 | 6.87 | 16.24% | |
| IDEV | iShares Core MSCI International Developed Markets ETF | 89.16 | 10.54 | 13.40% | |
| AVDE | Avantis International Equity ETF | 89.24 | 11.68 | 15.06% | |
| DFAI | Dimensional International Core Equity Market ETF | 41.41 | 5.45 | 15.15% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.